Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: A Children's Oncology Group study (CCG‐1941)

Re‐induction outcomes vary for children with acute lymphoblastic leukemia (ALL) and marrow relapse. We explored possible relationships among asparaginase (ASNase) activity levels, asparagine (ASN) depletion, anti‐ASNase antibody titers, and response to re‐induction therapy in children and adolescents with ALL and an ‘early’ first marrow relapse.

[1]  W. Evans,et al.  Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. , 2005, Blood.

[2]  L. Boxer,et al.  A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia. , 2005, Cancer research.

[3]  R. Pieters,et al.  Cellular drug resistance in childhood leukemia , 2005, Annals of Hematology.

[4]  H. Sather,et al.  Asparaginase Antibody and Asparaginase Activity in Children With Higher-Risk Acute Lymphoblastic Leukemia: Children's Cancer Group Study CCG-1961 , 2004, Journal of pediatric hematology/oncology.

[5]  D. Voehringer,et al.  L-asparaginase kills lymphoma cells by apoptosis , 2004, Cancer Chemotherapy and Pharmacology.

[6]  M. D. Boer,et al.  Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL , 2003, Leukemia.

[7]  J. Neglia,et al.  A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. , 2002, Blood.

[8]  M. Kilberg,et al.  Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells. , 2001, The Biochemical journal.

[9]  M. Kilberg,et al.  Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells. , 2001, The Biochemical journal.

[10]  K. Weinberg,et al.  Development of a double-drug-resistant human leukemia model to cytosine arabinoside and L-asparaginase: evaluation of cross-resistance to other treatment modalities. , 2001, Anticancer research.

[11]  B. Pollock,et al.  Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study , 2000 .

[12]  B. Pollock,et al.  Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. , 2000, Blood.

[13]  M. Relling,et al.  Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Amylon,et al.  Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study , 1999, Leukemia.

[15]  B. Asselin.  The Three Asparaginases , 1999 .

[16]  B. Asselin,et al.  The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. , 1999, Advances in experimental medicine and biology.

[17]  M. Relling,et al.  Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia , 1998, Leukemia.

[18]  T. Ueno,et al.  Cell cycle arrest and apoptosis of leukemia cells induced by L-asparaginase , 1997, Leukemia.

[19]  S. Schuster,et al.  Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. , 1997, The American journal of physiology.

[20]  J. Boos,et al.  Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia , 1997, British journal of haematology.

[21]  R. Pieters,et al.  In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. , 1997, Blood.

[22]  M. Zucchetti,et al.  L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  H. Jürgens,et al.  Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. , 1996, European journal of cancer.

[24]  R. Gatti,et al.  Characterization of apoptotic phenomena induced by treatment with L-asparaginase in NIH3T3 cells. , 1995, Experimental cell research.

[25]  M. Zucchetti,et al.  Determination of L-asparagine in biological samples in the presence of L-asparaginase. , 1994, Journal of chromatography. B, Biomedical applications.

[26]  D. Coppola,et al.  Comparative pharmacokinetic studies of three asparaginase preparations. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  D. Coppola,et al.  Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor. , 1991, Cancer research.

[28]  I. Andrulis,et al.  Molecular and genetic characterization of human cell lines resistant tol-asparaginase and albizziin , 1990, Somatic cell and molecular genetics.

[29]  H. Mikawa,et al.  Biochemical characterization of U937 cells resistant to L-asparaginase: the role of asparagine synthetase. , 1989, Leukemia.

[30]  N. Cheung,et al.  Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement. , 1986, The American journal of pediatric hematology/oncology.

[31]  J. Jolivet,et al.  Sensitive analysis of asparagine and glutamine in physiological fluids and cells by precolumn derivatization with phenylisothiocyanate and reversed-phase high-performance liquid chromatography. , 1986, Journal of chromatography.

[32]  V. Wahn,et al.  Anaphylaxis to L-asparaginase during treatment for acute lymphoblastic leukemia in children--evidence of a complement-mediated mechanism. , 1985, Pediatric research.

[33]  R. Gelber,et al.  Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. , 1983, Cancer research.

[34]  R. Riccardi,et al.  L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. , 1981, Cancer research.

[35]  M. Nesbit,et al.  Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. , 1979, The American journal of pediatric hematology/oncology.

[36]  J. Zajączkowski,et al.  Immunological aspects of L-asparaginase treatment in children with lymphoproliferative disease. , 1976, Helvetica paediatrica acta.

[37]  T. Danilova,et al.  [Characteristics of asparaginase from Escherichia coli at different stages of purification]. , 1976, Prikladnaia biokhimiia i mikrobiologiia.

[38]  K. Ellem,et al.  Nutritional effects on precursor uptake and compartmentalization of intracellular pools in relation to RNA synthesis. , 1975, Biochimica et biophysica acta.

[39]  D. Killander,et al.  Studies on antibody formation in patients treated with L-asparaginase. , 1970, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[40]  J. Kidd.  Asparaginase and cancer--yesterday and today. , 1970, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[41]  A. Khan,et al.  Neutralizing precipitin in the serum of a patient treated with L-asparaginase. , 1969, The Journal of laboratory and clinical medicine.